Teva announced the launch of Budesonide Inhalation Suspension, the generic version of AstraZeneca‘s Pulmicort Respules.   

Pulmicort Respules are indicated as maintenance treatment to control and prevent asthma symptoms in patients aged 12 months–8 years. 

RELATED: Asthma Treatments: Inhalations Chart

Budesnide is an anti-inflammatory corticosteroid that exhibits potent glucocorticoid activity and weak mineralocorticoid activity. Corticosteroids have been shown to have a wide range of inhibitory activities against multiple cell types (eg, mast cells, eosinophils, neutrophils, macrophages, lymphyocytes), and mediators (eg, histamine, eicosanoids, leukotrienes, and cytokines) involved in allergic- and non-allergic-mediated inflammation.

Budesonide Inhalation Suspension is available as a 1mg/2mL strength in 30-count (6 x 5 ampules) cartons. 

For more information call (888) 838-2872 or visit